Oppenheimer Maintains Outperform on Biogen, Raises Price Target to $295
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained an Outperform rating on Biogen (NASDAQ:BIIB) and increased the price target from $280 to $295.
December 18, 2023 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reaffirmed Biogen's Outperform rating and raised the price target to $295, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Jay Olson suggests a strong conviction in Biogen's future performance. This typically instills confidence in investors and can lead to a short-term increase in the stock price as market participants react to the analyst's upgraded outlook.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100